Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | EBP | Q15125 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228127 | 0.99 | ESR1 (0.51) | ESR1ESR2LTA4HEBPSIGMAR1 | |
| SCHEMBL229529 | 0.99 | ESR1 (0.51) | ESR1ESR2LTA4HEBPSIGMAR1 | |
| SCHEMBL229524 | 0.95 | ESR1 (0.46) | ESR1ESR2LTA4HEBPSIGMAR1 | |
| SCHEMBL228940 | 0.93 | ESR1 (0.58) | ESR1ESR2LTA4HHRH3 | |
| SCHEMBL226484 | 0.93 | ESR1 (0.58) | ESR1ESR2LTA4HHRH3 | |
| SCHEMBL229552 | 0.92 | ESR1 (0.46) | ESR1ESR2LTA4HEBPSIGMAR1 | |
| SCHEMBL229487 | 0.91 | ESR1 (0.46) | ESR1ESR2LTA4HEBPSIGMAR1 | |
| SCHEMBL229053 | 0.91 | ESR1 (0.46) | ESR1ESR2LTA4HEBPSIGMAR1 | |
| SCHEMBL229287 | 0.91 | ESR1 (0.54) | ESR1ESR2HRH3DRD2HRH1 | |
| SCHEMBL227944 | 0.91 | ESR1 (0.54) | ESR1ESR2HRH3DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885LTA4H 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.